BOD Australia Ltd - Prescription sales off to a strong start in CY2020
BOD Australia Ltd (ASX:BDA)

Prescription sales off to a strong start in CY2020

Document   View Announcement
Published Feb 18, 2020

What happened?

What's happened?

Bod Australia Limited (“Bod”, ASX: BDA) reported a strong start to MediCabilis™ prescription sales in 2020 with 373 prescriptions filled in January, the third largest month on record.

What are the details?

Bod has now filled a total of 2,330 prescriptions since the sale of MediCabilis™ commenced in January 2019 when the first prescription was filled. Material growth in prescription numbers during 2020 is expected given the Company’s pending entry into the UK market this month, and the introduction of the 2.5% and 10% MediCabilis™ products as previously announced in Q3.

CEO's summary

Jo Patterson CEO of BOD Australia Ltd has provided a statement.
Jo Patterson
Jo Patterson
CEO, BOD Australia Ltd

"“Growth in prescription numbers for January is very encouraging and we are pleased to witness this steady increase in sales. Over the course of CY2020 we anticipate prescription volumes will grow significantly given two key events. Firstly, our planned UK market entry, which is happening this month, and the commencement of sales of the two new products we are introducing. As recently flagged, the 2.5% and 10% CBD isolate products grows our addressable market by 32% which is material. Added to which, there is much less competition in this segment of the market so we have a great opportunity and a larger sales footprint. Bod is therefore well primed to drive prescription number growth.”

Question   Ask Jo Patterson a question...

Download Announcement

View this announcement as well as our full profile on the company.
Document   View Announcement
View BDA's Full Profile Arrow Forward

Comments

Share your thoughts about this announcement...
Similar articles
Bod continues to achieve strong revenue growth in FY2020
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) advises that it has achieved strong revenue growth in recent months...
3 years ago
Bod continues to achieve upward trajectory in medicinal cannabis prescriptions
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has advised that it is continuing to experience significant uptake...
3 years ago
First medical cannabis prescriptions received from UK patients participating in Project Twenty21
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has confirmed first prescriptions of the Company’s MediCabilis™ med...
3 years ago
Around the web
Why these ASX firms are shying away from the pot stock label – Part Two
Neurotech says due to often negative publicity around cannabis companies it tends not to promote it...
via stockhead.com.au
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their...
via stockhead.com.au
Weed Week: Decriminalising cannabis could save Aussie tax payers billions every year
Penington Institute says pot-related law enforcement costs us $1.7 billion a year   Local cannabis...
via stockhead.com.au
Powered by  
  • Company
    BOD Australia Ltd
  • Website
  • Sector
    Distributors
  • Industry
    Distributors
  • Code
    ASX:BDA
  • Socials
View BOD Australia Ltd's Profile

How do I invest?

Considering investing in BOD Australia Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:BDA

    On your online investment platform search for the stock ticker code ASX:BDA to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Trade for $9.50 Arrow Forward
Up